Leuconostoc mesenteroides capable of adjusting intestinal flora and application of leuconostoc mesenteroides
By screening and identifying PM10 of the Essentialis, it was found that it could regulate the intestinal flora of mice, solving the gap in the study on the influence of the intestinal microorganisms of the Essentialis, achieving the effect of increasing the abundance of specific strains, and having great significance. Application prospects.
Patent Information
- Application Number
- CN202411528036.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-30
- Publication Date
- 2025-01-10
AI Technical Summary
Currently, there is limited research on the impact of Aspergillus enterosomes on the composition and diversity of intestinal microorganisms, and there is a lack of systematic understanding of its regulatory role.
A strain of PM10 from bamboo shoots was screened and identified. Through acid-resistant bile salt resistance and mouse gavage experiments, it was found that both live and dead bacteria can significantly improve the Bacteroides in the intestine of mice. Relative abundance of Lactobacillus and Ackermans.
Aspergillus PM10 has good acid and bile salt resistance, can regulate the intestinal flora in mice, significantly increase the abundance of specific strains, and has the potential to become a new microbial preparation in functional foods.
Smart Images
Figure CN119286707A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microorganisms, and specifically relates to a strain of Leuconostoc mesenteroides capable of regulating intestinal flora and an application thereof. Background Art
[0002] Leuconostoc mesenteroides is an important species of the genus Leuconostoc in lactic acid bacteria. It is widely found on the surface of plants and is often used in the production and silage of fermented dairy products, pickles, and fruit wine. It has a long history of consumption and application. Studies on the microbial community of naturally fermented vegetables have shown that Leuconostoc mesenteroides plays an important role in the natural fermentation process. In order to meet the demand for high-quality food, Leuconostoc mesenteroides is separated and purified from fermented foods and used as a food starter. Compared with other lactobacillus starters, Leuconostoc mesenteroides can tolerate high concentrations of salt and sugar, start fermentation, and produce carbon dioxide and acid, which can quickly reduce the pH value of the fermentation system and create an anaerobic environment for the subsequent growth of lactobacilli. At the same time, it inhibits the growth of spoilage bacteria, maintains the color of vegetables, and produces beneficial metabolites. At present, Leuconostoc mesenteroides is widely used in fermented foods to improve the flavor and taste of the products, thereby producing high-quality fermented foods.
[0003] In recent years, the potential probiotic properties of Leuconostoc mesenteroides have received increasing attention. In vitro studies have shown that Leuconostoc mesenteroides shows a high survival rate in the stomach and intestines, adheres to Caco-2 and HT-29 cells, and has inhibitory effects on pathogens such as Escherichia coli, Salmonella, and Staphylococcus aureus. In animal models, Leuconostoc mesenteroides can maintain and restore the intestinal microbial composition of diseased mice. These studies have shown that Leuconostoc mesenteroides has potential beneficial effects on the composition and diversity of intestinal microorganisms and intestinal mucosa, and is strain-specific. However, current research on this aspect is limited and confined to specific disease models, and research on how Leuconostoc mesenteroides affects intestinal microorganisms is still blank. Summary of the invention
[0004] In order to study the effect of Leuconostoc mesenteroides on intestinal flora, the present invention screened a strain PM10 suspected to be Leuconostoc mesenteroides from bamboo shoots, and identified the strain as Leuconostoc mesenteroides through morphological and molecular biological identification. The present invention found that Leuconostoc mesenteroides PM10 has good acid and bile resistance through acid and bile resistance performance detection and mouse gavage experiment, and its live and dead bacteria can increase the relative abundance of Bacteroides sp., Lactobacillus sp. and Akkermansia sp. strains in the mouse intestine.
[0005] In order to solve the above technical problems and achieve corresponding technical effects, the present invention specifically provides the following technical solutions:
[0006] The first object of the present invention is to provide a strain of Leuconostoc mesenteroides PM10, which is deposited in the China Center for Type Culture Collection with a deposit number of CCTCC NO: M 20232146, a deposit date of November 8, 2023, and a deposit address of Wuhan University, Wuhan, China.
[0007] The second object of the present invention is to provide the use of the above-mentioned Leuconostoc mesenteroides PM10 in regulating intestinal flora, wherein the use is to increase the relative abundance of Bacteroides sp., Lactobacillus sp. and Akkermansia sp. strains in the intestine.
[0008] The third object of the present invention is to provide the use of the above-mentioned Leuconostoc mesenteroides PM10 in the preparation of functional foods.
[0009] The fourth object of the present invention is to provide a bacterial agent containing the above-mentioned Enterococcus mesenteroides PM10.
[0010] In one embodiment of the present invention, the bacterial agent contains live or dead bacteria of Leuconostoc mesenteroides PM10.
[0011] A fifth object of the present invention is to provide an application of the above-mentioned bacterial agent in regulating intestinal flora, wherein the application is to increase the relative abundance of Bacteroides sp., Lactobacillus sp. and Akkermansia sp. strains in the intestine.
[0012] The sixth object of the present invention is to provide the use of the above-mentioned bacterial agent in the preparation of functional foods.
[0013] In one embodiment of the present invention, the functional food can be used to increase the relative abundance of Bacteroides sp., Lactobacillus sp. and Akkermansia sp. strains in the intestine.
[0014] The seventh object of the present invention is to provide a functional food containing the above-mentioned Enterococcus mesenteroides PM10 or the above-mentioned bacterial agent.
[0015] The eighth object of the present invention is to provide the use of the above functional food in increasing the relative abundance of Bacteroides sp., Lactobacillus sp. and Akkermansia sp. strains in the intestine.
[0016] Beneficial effects of the present invention:
[0017] The present invention screened a strain PM10 suspected to be Leuconostoc mesenteroides from bamboo shoots, and identified the strain as Leuconostoc mesenteroides through morphological and molecular biological identification. The present invention found that Leuconostoc mesenteroides PM10 had good acid and bile resistance through acid and bile resistance detection; through mouse gavage experiments, it was found that both live and dead bacteria of Leuconostoc mesenteroides PM10 had the effect of regulating the intestinal flora of mice, and live bacteria of Leuconostoc mesenteroides PM10 could significantly increase the relative abundance of Bacteroides sp., Lactobacillus sp. and Akkermansia sp. in the intestinal tract of mice, and dead bacteria of Leuconostoc mesenteroides PM10 could significantly increase the relative abundance of Bacteroides sp. and Akkermansia sp. in the intestinal tract of mice. Therefore, as a probiotic, Leuconostoc mesenteroides PM10 is expected to become a new type of microbial preparation used in the production of functional foods and has great application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 This is the colony characteristic diagram of Leuconostoc mesenteroides PM10;
[0019] Figure 2 This is the bacterial characteristic diagram of Leuconostoc mesenteroides PM10;
[0020] Figure 3 The results of the acid and bile salt resistance test of Leuconostoc mesenteroides PM10 and MR6 are shown in the figure; Figure 3 A in the figure is the acid resistance test result of Leuconostoc mesenteroides PM10 and MR6. Figure 3 B in the figure is the test result of choline resistance of Leuconostoc mesenteroides PM10 and MR6;
[0021] Figure 4 This is the result diagram of the effect of Leuconostoc mesenteroides PM10 and MR6 on the body weight of mice;
[0022] Figure 5 This is the result diagram of the effects of Leuconostoc mesenteroides PM10 and MR6 on the organ indexes of mice;
[0023] Figure 6This is the result of the effect of Leuconostoc mesenteroides PM10 and MR6 on the weight of the colon and cecum of mice; Figure 6 A in the figure is the effect of Leuconostoc mesenteroides PM10 and MR6 on the total colon weight of mice. Figure 6 B in the figure shows the effect of Leuconostoc mesenteroides PM10 and MR6 on the colon wall weight of mice. Figure 6 C in the figure is the effect of Leuconostoc mesenteroides PM10 and MR6 on the total weight of mouse cecum. Figure 6 D in the figure is the effect of Leuconostoc mesenteroides PM10 and MR6 on the cecal wall weight of mice;
[0024] Figure 7 This is a graph showing the effects of Leuconostoc mesenteroides PM10 and MR6 on the fecal flora composition of mice. DETAILED DESCRIPTION
[0025] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with specific implementation methods and the accompanying drawings of the specification. The embodiments described in the present invention are not all embodiments of the present invention. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in the field without creative work are within the scope of protection of the present invention. The experimental methods used in the following embodiments are conventional methods unless otherwise specified, and the materials, reagents and instruments used are conventional materials, reagents and instruments in the field unless otherwise specified, and those skilled in the art can obtain them through commercial channels.
[0026] The Leuconostoc mesenteroides PM10 screened by the present invention is deposited in the China Center for Type Culture Collection, with a deposit number of CCTCC NO: M 20232146, a deposit date of November 8, 2023, and an address of the depository unit of Wuhan University, Wuhan, China.
[0027] The culture medium involved in the present invention is as follows:
[0028] MRS solid culture medium: peptone 10g / L, beef extract 10g / L, glucose 20g / L, sodium acetate 2g / L, yeast powder 5g / L, diammonium hydrogen citrate 2g / L, K2HPO4·3H2O 2.6g / L, MgSO4·7H2O 0.1g / L, MnSO4·H2O 0.05g / L, Tween 80 1mL / L, agar powder 15g / L.
[0029] MRS liquid culture medium: peptone 10g / L, beef extract 10g / L, glucose 20g / L, sodium acetate 2g / L, yeast powder 5g / L, diammonium hydrogen citrate 2g / L, K2HPO4·3H2O 2.6g / L, MgSO4·7H2O 0.1g / L, MnSO4·H2O 0.05g / L, Tween 80 1mL / L.
[0030] Example 1: Isolation, screening, identification and preservation of Leuconostoc mesenteroides PM10
[0031] 1. Isolation and screening of strain PM10
[0032] Bamboo shoots from Hefei were used as samples. The bamboo shoot samples were homogenized and 1 mL was diluted 10-fold to 10 with sterile saline. -6 Then take 100 μL of each dilution factor of 10 -4 , 10 -5 , 10 -6 The dilution was plated on MRS solid culture medium, inverted and cultured at 37°C for 48h, and the colony morphology was observed and recorded; colonies of different morphologies on the MRS solid culture medium were picked for streaking separation, and after static culture at 37°C for 48h, single colonies of different morphologies on the MRS solid culture medium were picked for streaking separation again until pure single colonies with consistent morphology were obtained; the colony morphology of single colonies was observed, and the obtained colonies were examined by microscopy, Gram staining, and physiological and biochemical characteristics. The strains with small, round, milky white, raised, smooth colonies, spherical bacterial morphology, facultative anaerobicity, and positive Gram staining results were selected, and two strains that may be Leuconostoc mesenteroides were obtained, and they were named PM10 (the colony characteristics of PM10 are shown in Figure 1 The bacterial characteristics of PM10 are shown in Figure 2 ) and MR6. Figure 1 As shown, the diameter of strain PM10 in MRS solid medium is between 0.3 and 2 mm, the front morphology is round, the edges are neat, milky white, opaque, and the surface is moist and smooth; Figure 2 As shown, strain PM10 was Gram-positive and the cells were spherical.
[0033] 2. Identification of strain PM10
[0034] The strains PM10 and MR6 were inoculated into MRS liquid culture medium, respectively, and cultured at 37°C for 20 to 24 hours to obtain bacterial liquid, and the bacteria were collected by centrifugation. The genomic DNA was extracted using a bacterial genome extraction kit, and the genomic DNA was used as a template to amplify the 16S rDNA gene sequence using universal primers 27F and 1492R. The purified PCR products were connected and transformed, and the positive clones were sent to Shanghai Lingen Biotechnology Co., Ltd. for sequencing. The sequencing results showed that the 16S rDNA nucleotide sequence of strain PM10 was as shown in SEQ ID NO.1. The sequence obtained by sequencing was uploaded to NCBI's Blast for nucleic acid sequence alignment. The results showed that the 16S rDNA gene sequence of strain PM10 had the highest similarity with the 16S rDNA gene sequence of Leuconostoc mesenteroides S-15, which was 99.86%, so strain PM10 was identified as Leuconostoc mesenteroides. At the same time, based on the comparison results of the 16S rDNA gene sequence of strain MR6 in NCBI, strain MR6 was also identified as Leuconostoc mesenteroides.
[0035] SEQ ID NO.1:
[0036]
[0037] 3. Storage of strain PM10
[0038] Single colonies of strain PM10 and strain MR6 were picked and inoculated into MRS liquid culture medium respectively, and cultured at 37°C for 20 to 24 hours to obtain bacterial liquid; 1 mL of bacterial liquid was taken into a bacterial preservation tube, and after centrifugation at 6000 rpm for 3 minutes, the supernatant was discarded, and the bacterial mud was resuspended in 30% (v / v) glycerol solution, and stored at -80°C.
[0039] Example 2: Acid and bile resistance test of Leuconostoc mesenteroides PM10
[0040] 1. Acid resistance test of Leuconostoc mesenteroides PM10
[0041] The preserved strain PM10 and strain MR6 were streaked on MRS solid culture medium, inverted and cultured at 37°C for 48 hours, and single colonies in the MRS solid culture medium were picked and placed in MRS liquid culture medium, statically cultured at 37°C for 20-24 hours, and activated for two generations to obtain activated strains; the activated strains were inoculated into MRS liquid culture medium, statically cultured at 37°C for 20-24 hours to obtain bacterial liquid, centrifuged at 6000g for 10 minutes, and the cells were collected in two 1.5mL centrifuge tubes, washed twice with physiological saline, and centrifuged to collect bacterial mud, wherein the cells in the two centrifuge tubes of each strain were resuspended in equal volumes of simulated gastric fluid of different pH, and the number of live bacteria in the bacterial liquid was adjusted to ≥10 by spectrophotometer. 9 CFU / mL, culture at 37℃ for 3h, and count the viable bacteria on the plate before culture and at 1h, 2h and 3h of culture, with two parallels for each dilution.
[0042] Preparation of simulated gastric fluid: Pepsin (1:10000) was dissolved in sterile physiological saline (0.9% w / v, pH adjusted to 2.0 and 3.0 with hydrochloric acid) to a final concentration of 3 g / L, and filtered through a 0.22 μm sterile filter membrane.
[0043] 2. Bile salt resistance test of Leuconostoc mesenteroides PM10
[0044] The preserved strain PM10 and strain MR6 were streaked on MRS solid medium, inverted and cultured at 37°C for 48 hours, and single colonies in the MRS solid medium were picked and placed in MRS liquid medium, statically cultured at 37°C for 20-24 hours, and activated for two generations to obtain activated strains; the activated strains were inoculated into MRS liquid medium, statically cultured at 37°C for 20-24 hours to obtain bacterial liquid, centrifuged at 6000g for 10 minutes, and the cells were collected in three 1.5mL centrifuge tubes, washed twice with physiological saline, and centrifuged to collect bacterial mud, wherein the cells in the three centrifuge tubes of each strain were resuspended in equal volumes of simulated intestinal fluid with different bile salt concentrations, and the number of live bacteria in the bacterial liquid was adjusted to ≥10 by spectrophotometer. 9 CFU / mL, cultured at 37℃ for 6h, and plate live bacteria counts were performed before culture and at 2h, 4h and 6h.
[0045] Preparation of simulated intestinal fluid: Dissolve trypsin (1:250) in sterile saline (0.9% w / v, adjust pH to 8.0 with NaOH) to a final concentration of 1 g / L, and add bile salts to final concentrations of 0.1%, 0.2% and 0.3%, respectively, and filter through a 0.22 μm sterile filter membrane.
[0046] Depend on Figure 3 It can be seen that the number of live bacteria of strain PM10 in simulated gastric fluid with a pH of 2 for 3 hours is 4.70×10 9 CFU / mL, the survival rate was 65%; the 3h survival rate of strain MR6 in simulated gastric fluid with a pH of 3 was high, 58.59%, and the 3h survival rate in simulated gastric fluid with a pH of 2 was significantly reduced (see Figure 3 The survival rates of strain PM10 at 0.1%, 0.2% and 0.3% bile salt concentrations were 89.39%, 74.71% and 70.18% respectively for 6 hours, while the survival rate of strain MR6 at 0.2% bile salt concentration was significantly decreased to 58.94% for 6 hours (see Figure 3 B in the figure). These results indicate that both Leuconostoc mesenteroides PM10 and Leuconostoc mesenteroides MR6 have good acid and bile resistance, and the acid and bile resistance of Leuconostoc mesenteroides PM10 is better than that of Leuconostoc mesenteroides MR6. Furthermore, the present invention has made a patent deposit for Leuconostoc mesenteroides PM10, and the deposit information is as follows: the depository is China Center for Type Culture Collection, the deposit number is CCTCC NO: M 20232146, the deposit date is November 8, 2023, and the depository address is Wuhan University, Wuhan, China.
[0047] Example 3: Effect of Leuconostoc mesenteroides PM10 on the composition of intestinal flora in mice
[0048] 1. Preparation of intragastric fluid for Leuconostoc mesenteroides PM10 and Leuconostoc mesenteroides MR6
[0049] Streak strains PM10 and MR6 on MRS solid culture medium, invert and culture at 37°C for 48 hours, pick single colonies from MRS solid culture medium and place in MRS liquid culture medium, culture at 37°C for 20-24 hours, activate two generations continuously to obtain culture. Inoculate the culture into MRS liquid culture medium, enrich and culture at 37°C for 20-24 hours, centrifuge the obtained bacterial liquid at 8000g for 10 minutes to obtain bacterial sludge, wash it three times with sterile saline and collect the bacterial sludge. Resuspend the collected bacterial sludge with sterile 30% (v / v) glycerol solution to obtain live bacterial suspensions of strains PM10 and MR6, respectively, and store them in a -80°C refrigerator. Before gavage, adjust the concentration of the live bacterial suspension to ≥1×10 10 CFU / mL, and the live bacterial lavage solution of strains PM10 and MR6 was obtained. The live bacterial suspension of strains PM10 and MR6 was centrifuged at 8000g for 15min, washed and resuspended with sterile saline, and then placed in a sterilizing pot at 90℃ for 20min to obtain the dead bacterial lavage solution of strains PM10 and MR6 (the concentration was adjusted to ≥1×10 10 CFU / mL), and the blank group was gavaged with the same amount of sterile saline as the experimental group every day.
[0050] 2. Experimental Animals
[0051] SPF 8-week-old male C57BL / 6J mice were purchased from Weitonglihua Experimental Animal Technology Co., Ltd. The environment was strictly controlled at 22°C, with 12 h light / darkness, and the mice were free to eat and drink.
[0052] 3. Experimental methods
[0053] Fifty SPF 8-week-old male C57BL / 6J mice were randomly divided into 5 groups, 10 mice in each group, namely, blank group, PM10 live bacteria group, PM10 dead bacteria group, MR6 live bacteria group and MR6 dead bacteria group. Each group was gavaged with 0.2 mL of sterile saline, PM10 live bacteria gavage solution, PM10 dead bacteria gavage solution, MR6 live bacteria gavage solution and MR6 dead bacteria gavage solution every day, respectively. The concentration of the gavage solution containing the strain was 1×10 10 CFU / mL. After 7 days of adaptation, mice were gavaged for a total of 28 days, during which time they were free to eat and drink, and were weighed every day. After the experiment, the mouse feces were collected, and the organs were collected and weighed after the mice were killed. The Fast DNA Spin Kit for Feces was used to extract the fecal bacterial metagenomics of each group of mice, and the 16S V3-V4 region sequence was amplified by PCR, and the composition differences of the intestinal flora in the fecal samples were detected by a second-generation sequencer.
[0054] Depend on Figure 4It can be seen that after 7 days of adaptation, the average weight of each group of mice was between 20 and 23g. After the experiment, the weight of each group of mice increased to between 22 and 24g. During the experiment, there was no significant difference between the weight of mice in the four treatment groups of PM10 and MR6 live bacteria and dead bacteria and the blank group. After the experiment, the organ index of the mice was measured. The results are as follows: Figure 5 As shown in the figure, the organ indexes of the heart, liver, lung, kidney and spleen of the mice in the four treatment groups of live bacteria and dead bacteria of strains PM10 and MR6 were not significantly different from those of the blank group mice (p>0.05). These results indicate that Leuconostoc mesenteroides PM10 and Leuconostoc mesenteroides MR6 have no effect on the body weight and organ indexes of mice.
[0055] After the experiment, the colon and cecum of the mice were collected and their total weight and wall weight were measured. Figure 6 As shown, the total weight and wall weight of the colon and cecum of mice in the four treatment groups that were gavaged with live bacteria of strains PM10 and MR6 and dead bacteria of strains MR6 were not significantly different from those in the blank group (p>0.05), which indicates that Enterobacter mesenteroides PM10 and Enterobacter mesenteroides MR6 have no effect on the colon and cecum of mice.
[0056] The composition of the mouse intestinal flora was analyzed by 16S rDNA sequencing. A total of 4,172,262 V3-V4 sequences were measured from mouse fecal samples, and a total of 156 genera were identified, such as Figure 7Among them, the relative abundance of Muribaculaceae was the highest, exceeding 57.97% in the intestinal tract of the blank group mice, and the relative abundance of this genus decreased slightly after gavage with strains PM10 and MR6. After gavage with live bacteria of strain PM10, the relative abundance of Bacteroides sp., Lactobacillus sp. and Akkermansia sp. in the intestinal tract of mice increased significantly, among which the relative abundance of Lactobacillus reached 6.4%; after gavage with dead bacteria of strain PM10, the relative abundance of Akkermansia in the intestinal tract of mice increased most significantly, which was 4.89%, followed by members of Bacteroides and Lactobacillus. Bacteroides is a resident bacteria in the intestine, involved in many important metabolic activities in the colon, and is an important cornerstone genus in the intestine; Akkermansia is the most promising next-generation probiotic, which has been widely reported to have the effects of alleviating obesity, type I and type II diabetes, cardiovascular disease, alcoholic fatty liver and regulating host immunity. After mice were gavaged with live bacteria of strain MR6, the relative abundance of Lactobacillus in the intestine increased to 0.82%, and the relative abundance of Bacteroides was not significantly different from that of the blank group; after gavage with dead bacteria of strain MR6, the relative abundance of Alistipes sp. increased most significantly, followed by Bacteroides and Akkermansia. These results show that Leuconostoc mesenteroides PM10 has the function of regulating intestinal flora and is expected to become a new type of microbial preparation for application in functional foods.
[0057] Example 4: Preparation method of Leuconostoc mesenteroides PM10 starter culture
[0058] The strain PM10 was streaked on MRS solid medium and cultured at 37°C for 48 hours to obtain a single colony. The single colony was selected and inoculated into MRS liquid medium and cultured at 37°C for 20 hours, and activated for two generations. The activated strain was inoculated into MRS liquid medium for enrichment culture to obtain bacterial liquid, which was centrifuged at 8000g for 10 minutes to collect bacterial mud, which was washed three times with sterile saline and resuspended with a protective agent to evenly disperse the bacteria in the protective agent and freeze-dried.
[0059] The protective agent contains: 120 g / L skim milk powder, 60 g / L trehalose, and 30 g / L sodium L-glutamate.
[0060] Although the present invention has been disclosed as above in the form of preferred embodiments, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.
Claims
1. A strain of Leuconostoc mesenteroides PM10, characterized in that: The deposit number is CCTCC NO: M 20232146.
2. The use of Leuconostoc mesenteroides PM10 according to claim 1 in regulating intestinal flora, characterized in that: The application is to increase the relative abundance of Bacteroides sp., Lactobacillus sp. and Akkermansia sp. strains in the intestine.
3. Use of the Leuconostoc mesenteroides PM10 according to claim 1 in the preparation of functional foods.
4. A bacterial agent containing the Leuconostoc mesenteroides PM10 according to claim 1.
5. The bacterial agent according to claim 4, characterized in that The bacterial agent contains live or dead bacteria of Leuconostoc mesenteroides PM10.
6. Use of the bacterial agent according to any one of claims 4 or 5 in regulating intestinal flora, characterized in that: The application is to increase the relative abundance of Bacteroides sp., Lactobacillus sp. and Akkermansia sp. strains in the intestine.
7. Use of the bacterial agent according to any one of claims 4 or 5 in the preparation of functional foods.
8. The use according to any one of claim 3 or claim 7, characterized in that: The functional food is used to increase the relative abundance of Bacteroides sp., Lactobacillus sp. and Akkermansia sp. strains in the intestinal tract.
9. A functional food containing the Leuconostoc mesenteroides PM10 according to claim 1 or the bacterial agent according to any one of claims 4 or 5.
10. Use of the functional food according to claim 9 for increasing the relative abundance of Bacteroides sp., Lactobacillus sp. and Akkermansia sp. strains in the intestine.